The Standard Group Plc is a multi-media organization with investments in media platforms spanning newspaper print operations, television, radio broadcasting, digital and online services. The Standard Group is recognized as a leading multi-media house in Kenya with a key influence in matters of national and international interest.

Standard Group Plc HQ Office,
The Standard Group Center,Mombasa Road.
P.O Box 30080-00100,Nairobi, Kenya.
Telephone number: 0203222111, 0719012111
Email: [email protected]

NEWS & CURRENT AFFAIRS

The Nairobian

WHO backs rollout of malaria vaccine for African children

Health & Science

By Reuters | Oct 07, 2021

**A child is vaccinated against malaria in Migowi, Malawi. World health officials first wanted to see how well the vaccine would work in Malawi, Ghana and Kenya before recommending its wider use.** [AP]

The World Health Organisation (WHO) said yesterday the only approved vaccine against malaria should be widely given to African children, potentially marking a major advance against a disease that kills hundreds of thousands of people annually.

The WHO recommendation is for RTS,S — or Mosquirix — a vaccine developed by British drugmaker GlaxoSmithKline.

Since 2019, 2.3 million doses of Mosquirix have been administered to infants in Ghana, Kenya and Malawi in a large-scale pilot programme coordinated by the WHO. The majority of those whom the disease kills are aged under five.

That programme followed a decade of clinical trials in seven African countries.

Keep Reading business

"This is a vaccine developed in Africa by African scientists and we're very proud," said WHO director-general Tedros Adhanom Ghebreyesus. "This vaccine is a gift to the world but its value will be felt most in Africa."

Malaria is far more deadly than Covid-19 in Africa. It killed 386,000 Africans in 2019, according to a WHO estimate, compared with 212,000 confirmed deaths from Covid-19 in the past 18 months.

The WHO says 94 per cent of malaria cases and deaths occur in Africa, a continent of 1.3 billion people. The preventable disease is caused by parasites transmitted to people by the bites of infected mosquitoes; symptoms include fever, vomiting and fatigue.

The Mosquirix recommendation was jointly announced in Geneva by the WHO's top advisory bodies for malaria and immunization, the Malaria Policy Advisory Group and the Strategic Advisory Group of Experts on Immunisation.

The vaccine's effectiveness at preventing severe cases of malaria in children is only around 30 per cent, but it is the only approved vaccine. The European Union's drugs regulator approved it in 2015, saying its benefits outweighed the risks.

In late 2015, the WHO expert panels called for a pilot programme in three to five African countries to inform a future decision about widespread use of the vaccine.

On Wednesday, nearly six years later and two years after the start of the pilots, the WHO panels recommended the vaccine be rolled out for children across African nations where malaria is endemic, alongside the other authorised means of preventing malaria such as bednets and spraying.

In 2019, the WHO said the fight against malaria had stalled. But it said yesterday that using the vaccine as an additional tool against the disease could save tens of thousands of lives each year.